Navigation Links
Guidant sold defective defibrillators with full knowledge

Guidant Corporation had projected in an internal report that some patients might die due to short circuits in a heart device, but did not publicize the flaw to retain // acceptability, company records show.

A company report shows Guidant had determined in mid-2002 that the consequences of the defibrillator’s electrical failure, though rare, could be 'life threatening.' Despite that assessment, the company kept selling potentially flawed devices and did not notify doctors about the defect until last spring, when the problem was about to be made public.

One of the Guidant records shows that the company projected in May, before disclosure of the defibrillator's problems, that about 0.15 percent of the units - or 15 units out of every 10,000 - were likely to short-circuit. In such episodes, Guidant estimated that 12 percent of the patients whose units failed, or about 1 in 10, would experience either a Severity Level 5 (death) or Severity Level 4 (life-threatening) event.

The Guidant documents were filed in a Texas state court by plaintiffs' lawyers in connection with a personal injury lawsuit involving the defibrillator known as Prizm 2 DR. The records appear to be the first internal Guidant documents to have emerged in court filings since the company began facing a wave of lawsuits this year.

Guidant officials have maintained that the company did nothing wrong.

The emergence of the Guidant records could intensify the company's legal problems as well as a broader debate about when manufacturers of heart devices should alert physicians about product risks.

In addition, New York State and the city of Bethlehem, Pa., have filed lawsuits against Guidant seeking reimbursement for device-related health care costs.

Another Guidant document filed in connection with the Texas lawsuit shows that the company determined in February that it would not reopen its own investigation into the device's problem until the n umber of failures exceeded a specific number at a given point.

In a posting on its Web site yesterday, Guidant said that it knew of two patient deaths associated with short circuits in the Prizm 2 DR and five other patient deaths associated with short circuits in devices called the Contak Renewal and Contak Renewal 2. The flaws are all associated with Guidant's use of an insulating material in a way that caused it to deteriorate.

Dr. William H. Maisel, a cardiologist at Beth Israel Deaconess Medical Center in Boston, said yesterday in a telephone interview that all heart device makers typically perform hazards assessments after discovering a device flaw. But Dr. Maisel said he remained troubled that Guidant d not disclose the data about the short circuits and the statistical analysis the company performed.

Largely as a result of the Guidant episode, device makers, doctors and the F.D.A. are trying to develop uniform guidelines for manufacturers to disclose product flaws to physicians. Doctors can then weigh such risks against those posed by added surgery in deciding whether to replace a device early.

Guidant initially said that it believed that the risk of replacing a Prizm 2 DR might outweigh those posed by the device itself. It was in early 2002 that it learned from reports that the Prizm 2 DR was prone to short-circuiting.

In April and November 2002, company engineers took steps to prevent the short-circuiting. But the company kept selling older models out of inventory even after an improved one was available.

In its June 2002 assessment, Guidant described the flaws 'overall health risk index' as 'very low.'

At about the same time that Guidant discovered the problem with the Prizm 2 DR, the company was awaiting approval from the F.D.A. to market the Contak Renewal.

Company officials have repeatedly declined to describe the steps they took, if any, at that time to determine if the Contak Rene wal might also short-circuit.

The Texas lawsuit, which is scheduled to begin in late February, could be the first Guidant case in the current wave of lawsuits to go to trial.

The company in its profit forecast said on Dec. 14 that it had received seven reports of deaths related to heart defibrillator failures since the company recalled 109,000 of the devices in June.

Boston Scientific and Johnson & Johnson are bidding to acquire Guidant.


'"/>




Related medicine news :

1. Need to use defibrillators
2. Spreading knowledge to doctors about herbal medicine
3. knowledge of proliferative sickle cell retinopathy can help Prevent eye trauma
4. India set to become the global knowledge hub
5. New law to protect traditional knowledge
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: